Acquired resistance to osimertinib in advanced lung cancer: A case report

被引：0
|
作者：
Xu, Jiayi [1 ,2 ]
Xu, Zikai [1 ]
Hong, Jianwei [2 ,3 ]
Zhou, Xiaoyu [1 ]
机构：
[1] Nantong Univ, Dept Resp & Crit Care Med, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Peoples R China
[2] Nantong Univ, Med Sch, Nantong 226001, Peoples R China
[3] Nantong Univ, Dept Gastroenterol, Affiliated Hosp, Nantong 226001, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2024年 / 47卷 / 08期
关键词：
D O I：
10.1016/j.asjsur.2024.04.116
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：3763 / 3764
页数：2
相关论文
共 50 条
  • [31] AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
    Murakami, Yuichi
    Kusakabe, Daiki
    Watari, Kosuke
    Kawahara, Akihiko
    Azuma, Koichi
    Akiba, Jun
    Taniguchi, Masahiko
    Kuwano, Michihiko
    Ono, Mayumi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [32] Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
    Lim, Sun Min
    Yang, San-Duk
    Lim, Sangbin
    Shim, Hyo Sup
    Cho, Byoung Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [33] Alectinib/crizotinibDiarrhoea and acquired resistance in lung adenocarcinoma: case report
    Reactions Weekly, 2018, 1730 (1) : 19 - 19
  • [34] OsimertinibAcquired resistance to osimertinib therapy: case report
    Reactions Weekly, 2018, 1707 (1) : 217 - 217
  • [35] Osimertinib/gefitinib/erlotinibDevelopment of resistance to osimertinib, gefitinib and erlotinib: case report
    Reactions Weekly, 2017, 1654 (1) : 269 - 269
  • [36] Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer
    Chen, Wu
    Yu, Danlei
    Sun, Shi-Yong
    Li, Feng
    ACTA BIOMATERIALIA, 2021, 129 : 258 - 268
  • [37] Osimertinib 160 mg daily for advanced non-small cell lung cancer with leptomeningeal metastasis: A case report
    Tsang, Maverick Wai-Kong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 5 - 7
  • [38] GefitinibDevelopment of acquired resistance to gefitinib with transformation of lung adenocarcinoma to metastatic small cell lung cancer: case report
    Reactions Weekly, 2022, 1899 (1) : 198 - 198
  • [39] Erlotinib/osimertinibInterstitial lung disease and acquired resistance in lung adenocarcinoma: case report
    Reactions Weekly, 2019, 1736 (1) : 104 - 104
  • [40] Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    Chmielecki, Juliann
    Gray, Jhanelle E.
    Cheng, Ying
    Ohe, Yuichiro
    Imamura, Fumio
    Cho, Byoung Chul
    Lin, Meng-Chih
    Majem, Margarita
    Shah, Riyaz
    Rukazenkov, Yuri
    Todd, Alexander
    Markovets, Aleksandra
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Ramalingam, Suresh S.
    NATURE COMMUNICATIONS, 2023, 14 (01)
12345